ADC Therapeutics SA (NYSE:ADCT) Stock Rated "Hold" by Sell-Side Analysts

Key Points

• ADC Therapeutics has a consensus “Hold” rating from six analysts: three buys, two holds, and one sell. The average 12-month price target is $5.00.
• ADCT shares opened at $1.52 and have traded between $0.78 and $4.98 over the past year; the stock was up 2.3%, with a market capitalization of approximately $194.7 million.
• The company exceeded quarterly expectations, reporting an adjusted loss of $0.11 per share versus the projected $0.22 loss and revenue of $19.25 million versus the $18.89 million estimate. Institutional investors own 41.1% of the stock.

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has been given a consensus rating of "Hold" by the six analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $5.00.

A number of analysts have recently commented on ADCT shares. Wall Street Zen upgraded ADC Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Guggenheim decreased their price objective on ADC Therapeutics to $5.00 and set a "buy" rating for the company in a report on Monday, August 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of ADC Therapeutics in a research report on Thursday, October 15th.

ADC Therapeutics Trading Up 2.3%

ADCT opened at $1.52 on Friday. The stock has a market capitalization of $194.70 million, a P/E ratio of -2.31 and a beta of 1.86. ADC Therapeutics has a 12 month low of $0.78 and a 12 month high of $4.98. The firm's fifty day simple moving average is $1.30 and its 200 day simple moving average is $2.48.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.11. The company had revenue of $19.25 million during the quarter, compared to analyst estimates of $18.89 million. On average, equities research analysts predict that ADC Therapeutics will post -0.80 EPS for the current fiscal year.

Hedge Funds Weigh In On ADC Therapeutics

Hedge funds have recently made changes to their positions in the business. AXQ Capital LP acquired a new stake in shares of ADC Therapeutics in the second quarter valued at approximately $29,000. R Squared Ltd bought a new stake in shares of ADC Therapeutics in the first quarter worth $38,000. Quantinno Capital Management LP lifted its position in shares of ADC Therapeutics by 36.0% in the first quarter. Quantinno Capital Management LP now owns 14,719 shares of the company's stock worth $55,000 after purchasing an additional 3,894 shares in the last quarter. Revolve Wealth Partners LLC acquired a new position in ADC Therapeutics during the second quarter worth $107,000. Finally, Sei Investments Co. boosted its holdings in ADC Therapeutics by 45.6% during the first quarter. Sei Investments Co. now owns 33,461 shares of the company's stock worth $125,000 after purchasing an additional 10,472 shares during the last quarter. 41.10% of the stock is owned by institutional investors.

About ADC Therapeutics

ADC Therapeutics SA NYSE: ADCT is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue.

The company's lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.